Literature DB >> 28964622

Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.

Diogo Torres1, Amanika Kumar1, Sumer K Wallace1, Jamie N Bakkum-Gamez1, Gottfried E Konecny2, Amy L Weaver3, Michaela E McGree3, Ellen L Goode4, William A Cliby1, Chen Wang5.   

Abstract

OBJECTIVE: To investigate the association between intraperitoneal (IP) disease dissemination patterns, residual disease (RD), surgical complexity, and molecular subtypes in advanced high-grade serous ovarian cancer (HGSOC).
METHODS: 741 patients with operable stage III-IV HGSOC undergoing primary debulking surgery at Mayo Clinic from 1994 to 2011 were categorized into four mutually exclusive IP disease dissemination patterns: upper abdominal (60%), miliary (16%), lower abdominal (15%), and pelvic (9%). Surgical complexity was classified as high, intermediate, or low; RD status was defined as 0, 0.1-0.5, 0.6-1.0, or >1cm; molecular subtype assignments were derived from expression profiling of tumors from 334 patients.
RESULTS: Patients with either miliary or upper abdominal dissemination patterns were less likely to achieve RD0 compared to patients with pelvic and lower abdominal dissemination patterns (25% vs. 9% and 62%, each P<0.001) despite higher surgical complexity (39% vs. 6% and 20%, each P<0.001). Among the subset with molecular subtype data, patients with mesenchymal subtype of tumors were more likely to have upper abdominal or miliary dissemination patterns compared to patients with differentiated, proliferative, or immunoreactive subtypes (90% vs. 77%, 70%, 69%, respectively, P<0.05).
CONCLUSIONS: IP disease dissemination patterns are associated with RD, surgical complexity, and tumor molecular subtypes. Patients with upper abdominal or miliary dissemination patterns are more likely to have mesenchymal HGSOC and in turn achieve lower rates of complete resection. This provides a plausible model for how the biologic behavior of molecular subtypes is manifest in disease and oncologic outcomes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28964622      PMCID: PMC5698116          DOI: 10.1016/j.ygyno.2017.09.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Bobbie S Gostout; Monica B Jones; C Robert Stanhope; Timothy O Wilson; Karl C Podratz; William A Cliby
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

2.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.

Authors:  Sumer Wallace; Amanika Kumar; Michaela Mc Gree; Amy Weaver; Andrea Mariani; Carrie Langstraat; Sean Dowdy; Jamie Bakkum-Gamez; William Cliby
Journal:  Gynecol Oncol       Date:  2017-01-31       Impact factor: 5.482

4.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Authors:  Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

5.  Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.

Authors:  Kevin H Eng; Kayla Morrell; Kristen Starbuck; Chandra Spring-Robinson; Aalia Khan; Dana Cleason; Levent Akman; Emese Zsiros; Kunle Odunsi; J Brian Szender
Journal:  Gynecol Oncol       Date:  2017-05-08       Impact factor: 5.482

6.  The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.

Authors:  Chad A Hamilton; Austin Miller; Caela Miller; Thomas C Krivak; John H Farley; Mildred R Chernofsky; Michael P Stany; G Scott Rose; Maurie Markman; Robert F Ozols; Deborah K Armstrong; G Larry Maxwell
Journal:  Gynecol Oncol       Date:  2011-06-17       Impact factor: 5.482

7.  Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.

Authors:  Giovanni D Aletti; Eric L Eisenhauer; Antonio Santillan; Allison Axtell; Giacomo Aletti; Christine Holschneider; Dennis S Chi; Robert E Bristow; William A Cliby
Journal:  Gynecol Oncol       Date:  2010-10-08       Impact factor: 5.482

8.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

9.  Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Authors:  Vasileios D Sioulas; Maria B Schiavone; David Kadouri; Oliver Zivanovic; Kara Long Roche; Roisin O'Cearbhaill; Nadeem R Abu-Rustum; Douglas A Levine; Yukio Sonoda; Ginger J Gardner; Mario M Leitao; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2017-02-21       Impact factor: 5.482

10.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

View more
  8 in total

Review 1.  Cholecystectomy, porta hepatis stripping, and omental bursectomy.

Authors:  Joo-Hyuk Son; Suk-Joon Chang
Journal:  Gland Surg       Date:  2021-03

2.  Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Authors:  Diogo Torres; Chen Wang; Amanika Kumar; Jamie N Bakkum-Gamez; Amy L Weaver; Michaela E McGree; Gottfried E Konecny; Ellen L Goode; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

Review 3.  Narrative review of liver mobilization, diaphragm peritonectomy, full-thickness diaphragm resection, and reconstruction.

Authors:  Wonkyo Shin; Jaehee Mun; Sang-Yoon Park; Myong Cheol Lim
Journal:  Gland Surg       Date:  2021-03

4.  Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:  Aline Talhouk; Joshy George; Chen Wang; Ellen L Goode; Susan J Ramus; Jennifer A Doherty; David D Bowtell; Michael S Anglesio; Timothy Budden; Tuan Zea Tan; Derek S Chiu; Stefan Kommoss; Huei San Leong; Stephanie Chen; Maria P Intermaggio; Blake Gilks; Tayyebeh M Nazeran; Mila Volchek; Wafaa Elatre; Rex C Bentley; Janine Senz; Amy Lum; Veronica Chow; Hanwei Sudderuddin; Robertson Mackenzie; Samuel C Y Leong; Geyi Liu; Dustin Johnson; Billy Chen; Aocs Group; Jennifer Alsop; Susana N Banerjee; Sabine Behrens; Clara Bodelon; Alison H Brand; Louise Brinton; Michael E Carney; Yoke-Eng Chiew; Kara L Cushing-Haugen; Cezary Cybulski; Darren Ennis; Sian Fereday; Renée T Fortner; Jesús García-Donas; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Teodora Goranova; Casey S Greene; Paul Haluska; Holly R Harris; Joy Hendley; Brenda Y Hernandez; Esther Herpel; Mercedes Jimenez-Linan; Chloe Karpinskyj; Scott H Kaufmann; Gary L Keeney; Catherine J Kennedy; Martin Köbel; Jennifer M Koziak; Melissa C Larson; Jenny Lester; Liz-Anne Lewsley; Jolanta Lissowska; Jan Lubiński; Hugh Luk; Geoff Macintyre; Sven Mahner; Iain A McNeish; Janusz Menkiszak; Nikilyn Nevins; Ana Osorio; Oleg Oszurek; José Palacios; Samantha Hinsley; Celeste L Pearce; Malcolm C Pike; Anna M Piskorz; Isabelle Ray-Coquard; Valerie Rhenius; Cristina Rodriguez-Antona; Raghwa Sharma; Mark E Sherman; Dilrini De Silva; Naveena Singh; Peter Sinn; Dennis Slamon; Honglin Song; Helen Steed; Euan A Stronach; Pamela J Thompson; Aleksandra Tołoczko; Britton Trabert; Nadia Traficante; Chiu-Chen Tseng; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Boris Winterhoff; Alicia Beeghly-Fadiel; Javier Benitez; Andrew Berchuck; James D Brenton; Robert Brown; Jenny Chang-Claude; Georgia Chenevix-Trench; Anna deFazio; Peter A Fasching; María J García; Simon A Gayther; Marc T Goodman; Jacek Gronwald; Michelle J Henderson; Beth Y Karlan; Linda E Kelemen; Usha Menon; Sandra Orsulic; Paul D P Pharoah; Nicolas Wentzensen; Anna H Wu; Joellen M Schildkraut; Mary Anne Rossing; Gottfried E Konecny; David G Huntsman; Ruby Yun-Ju Huang
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

5.  Lysophosphatidic acid modulates ovarian cancer multicellular aggregate assembly and metastatic dissemination.

Authors:  Yuliya Klymenko; Brandi Bos; Leigh Campbell; Elizabeth Loughran; Yueying Liu; Jing Yang; Oleg Kim; M Sharon Stack
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

6.  Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer.

Authors:  Martin Svoboda; Felicitas Mungenast; Andreas Gleiss; Ignace Vergote; Adriaan Vanderstichele; Jalid Sehouli; Elena Braicu; Sven Mahner; Walter Jäger; Diana Mechtcheriakova; Dan Cacsire-Tong; Robert Zeillinger; Theresia Thalhammer; Dietmar Pils
Journal:  Front Pharmacol       Date:  2018-08-07       Impact factor: 5.810

7.  Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?

Authors:  Ye Hu; Barbie Taylor-Harding; Yael Raz; Marcela Haro; Maria Sol Recouvreux; Enes Taylan; Jenny Lester; Joshua Millstein; Ann E Walts; Beth Y Karlan; Sandra Orsulic
Journal:  Front Cell Dev Biol       Date:  2020-07-17

8.  Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning.

Authors:  Alexandros Laios; Angeliki Katsenou; Yong Sheng Tan; Racheal Johnson; Mohamed Otify; Angelika Kaufmann; Sarika Munot; Amudha Thangavelu; Richard Hutson; Tim Broadhead; Georgios Theophilou; David Nugent; Diederick De Jong
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.